MetaCap

AbCellera Biologics (ABCL) vs ACADIA Pharmaceuticals (ACAD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbCellera Biologics (ABCL) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 176.1% versus a loss of 27.4%. Over five years, ACAD leads with a -8.9% price change compared with -30.7% for ABCL. AbCellera Biologics is the larger company by market cap ($3.16 billion vs $2.96 billion), about 1.1 times the size.

ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus -194.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABCL+176.07%ACAD-27.38%
+340%+146%-48%
Nov 21, 20251 yearNov 20, 2026
ABCL-38.67%ACAD-10.65%
+76%-10%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABCL versus ACAD key metrics
MetricABCLACAD
Share price$9.69$17.11
Market cap$3.16B$2.96B
1-day change-7.45%-2.73%
YTD return+183.33%-35.94%
1-year return+176.07%-27.38%
5-year return-30.74%-8.94%
P/E ratio (TTM)—8.07
Forward P/E—15.75
EPS (TTM)$-0.48$2.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.13M$1.07B
Revenue growth (YoY)+160.56%+11.87%
Net income (latest FY)$-146.41M$391.00M
Gross margin—91.69%
Operating margin-288.98%9.78%
Net margin-194.88%36.49%
52-week high$15.02$30.96
52-week low$2.75$15.86
Distance from 52-week high-35.46%-44.74%
Analyst consensusstrong_buybuy
Avg. price target upside+92.67%+77.21%
Average volume4.34M2.18M
Shares outstanding326.62M172.83M
Employees562796
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABCL has outperformed ACAD by 203.4 percentage points over the past year.
  • ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
  • AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +11.87%).

About AbCellera Biologics

ABCL stock →

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees

About ACADIA Pharmaceuticals

ACAD stock →

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees

ABCL vs ACAD FAQ

Which is bigger, AbCellera Biologics or ACADIA Pharmaceuticals?

AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.16B compared with $2.96B for ACADIA Pharmaceuticals (ACAD).

Which stock has performed better over the past year, ABCL or ACAD?

ABCL returned +176.07% over the past 12 months, compared with -27.38% for ACAD (price return, excluding dividends). Past performance does not predict future results.

Are AbCellera Biologics and ACADIA Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons